# NCT05642780 (NCT05642780)

> SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05642780
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Klus Pharma Inc.
- Conditions: Solid Tumor
- Interventions: SKB264; Pembrolizumab
- Enrollment: 240
- Primary outcome: Dose limiting toxicity (DLT) and adverse events (AEs)
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Prostate-specific antigen (PSA) response rate (Cohort D)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05642780